Loading clinical trials...
Loading clinical trials...
Peking Union Medical College Hospital
This study was used to study the diagnostic value of 68Ga-FAPI, a novel fibroblast activating inhibitor, in metastatic adenoid cystic carcinoma（ACC）
68Ga-FAPI is a positron labeled inhibitor of fibroblast activating protein, which has been widely used in malignant tumor imaging in recent years. Adenoid cystic carcinoma (ACC) is a rare epithelial malignant tumor, which usually originates from salivary glands. Its typical characteristics are long clinical course and high rate of distant metastasis. The purpose of this study was to investigate the clinical value of 68Ga Fapi pet/ct in metastatic adenoid cystic carcinoma.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Beijing, China
Start Date
October 1, 2021
Primary Completion Date
October 1, 2022
Completion Date
December 31, 2022
Last Updated
August 12, 2022
30
ESTIMATED participants
68Ga-FAPI
DRUG
Zhaohui Zhu
CONTACT
Lead Sponsor
Peking Union Medical College Hospital
NCT04883671
NCT03990571
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions